Top Medical Journal Retracts E-Cigarette Smoking Cessation Effectiveness Paper

Industry Insight by 2FIRSTS
Apr.15.2024
Top Medical Journal Retracts E-Cigarette Smoking Cessation Effectiveness Paper
JAMA retracts e-cigarette quitting study for major coding errors and doubts on accuracy, causing widespread concern and controversy.

Recently, the Journal of the American Medical Association (JAMA) retracted an article published two months ago about vaping e-cigarettes due to researchers notifying the editors of "significant coding errors" and other issues in the study.

Top Medical Journal Retracts E-Cigarette Smoking Cessation Effectiveness Paper
Withdrawal page | Image source: American Medical Association Journal

 

This paper titled "Effectiveness of e-cigarettes compared with varenicline and nicotine gum for smoking cessation: a randomized clinical trial" was originally published in the January 29th issue of JAMA Internal Medicine, led by Dr. Liu Zhaobo from the Smoking Control and Respiratory Disease Prevention Department at Beijing Friendship Hospital. The researchers in this study found that in terms of helping people quit smoking, using e-cigarettes is not inferior to prescription medications and is more effective than nicotine gum. The paper has garnered widespread attention in the medical community, non-professional media, and social media.

 

Top Medical Journal Retracts E-Cigarette Smoking Cessation Effectiveness Paper
Withdrawal notice | Image source: Journal of the American Medical Association

 

However, the article was later retracted.

 

The retraction notice for this paper was issued on March 29th as follows:

 

We have identified significant coding errors that are difficult to correct. We also found discrepancies in the calculations, which have raised doubts about the accuracy and reliability of the reported results. Therefore, we believe it is necessary to retract this article in order to maintain the integrity of scientific research and uphold the trust of our readers and the medical community. All co-authors have agreed to the retraction. We sincerely apologize for any inconvenience or confusion this may have caused.

 

According to the academic media Research Gate, Liu Zhao later responded to media inquiries via email, stating that the article was voluntarily retracted by the research team. He provided the following explanation in response:

 

As we explained to the editors of the Journal of the American Medical Association, following the publication of this paper, we plan to conduct a secondary analysis. In this process, we discovered that 109 participants who should have been in the NRT group were incorrectly placed in the EC group, and another 109 participants who should have been in the EC group were incorrectly placed in the NRT group. We immediately conducted an analysis and found that the main results had changed, therefore, we promptly wrote a letter to the editor explaining this issue and requesting the retraction of the paper.

 

Furthermore, according to publicly available information, no other articles have been affected by these issues. According to Clarivate's Web of Science, the research findings in question have been cited once.

 

Dr. Liu Chaobo, the first author of the paper by the group called 2FIRSTS, was contacted for details regarding the withdrawal notice. Dr. Liu stated that the withdrawal notice was clearly explained and no further information could be disclosed. Additionally, a call was made to the Tobacco Control and Cessation Center at the China-Japan Friendship Hospital to inquire about the details, but the staff member who answered the call claimed to be unaware of the situation.

 

2FIRSTS will continue to follow the latest developments on the research paper and its retraction.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Indonesian Police to Crack Down on Etomidate-Laced Vapes
Indonesian Police to Crack Down on Etomidate-Laced Vapes
Indonesia’s National Police Criminal Investigation Department (Bareskrim Polri) will continue to take enforcement action against users and distributors of etomidate-laced vape liquids, even though the substance is not yet classified as a narcotic. Brigadier General Eko Hadi Santoso, Director of Narcotics Crimes, said etomidate is an anaesthetic drug regulated under Health Law No. 17 of 2023, but has not been listed as a narcotic or psychotropic substance.
Oct.23 by 2FIRSTS.ai
Special Report | Anti-Vaping Campaign in the Baltics Goes Sideways
Special Report | Anti-Vaping Campaign in the Baltics Goes Sideways
2Firsts analyzes vaping regulations across the Baltic states. Following Latvia’s flavor ban, tax revenues fell and the black market expanded, while similar measures in Estonia and Lithuania have also failed to deliver results. The region’s anti-vaping policies are now triggering market imbalance and policy reassessment.
Oct.13
Imperial Brands Urges Retailers to Engage in Government Consultation on Tobacco and Vapes Bill
Imperial Brands Urges Retailers to Engage in Government Consultation on Tobacco and Vapes Bill
Imperial Brands is calling on UK retailers to take part in the Government’s consultation on the Tobacco and Vapes Bill, which will shape a new licensing framework for nicotine product sales across England, Wales and Northern Ireland. The Department of Health and Social Care’s call for evidence closes on 3 December 2025. Imperial Brands stresses this is a key chance for retailers to influence policy, support fair competition, and help curb illicit sales.
Nov.04
South Korea National Assembly Approves Bill to Regulate E-Cigarettes Under Tobacco Law After Nine Years of Debate
South Korea National Assembly Approves Bill to Regulate E-Cigarettes Under Tobacco Law After Nine Years of Debate
South Korea’s National Assembly Legislation and Judiciary Committee passed a long-debated amendment to the Tobacco Business Act on November 26, expanding the legal definition of tobacco to include synthetic nicotine e-cigarettes. The amendment aims to end the regulatory blind spot surrounding such products while ensuring transitional support for vape retailers and a grace period for compliance.
Nov.26 by 2FIRSTS.ai
Product | LOST MARY, ELFBAR & VOZOL Debut 2 mL Replaceable-Pod Devices: Three-Model Comparison
Product | LOST MARY, ELFBAR & VOZOL Debut 2 mL Replaceable-Pod Devices: Three-Model Comparison
Several brands launch 2 mL replaceable-pod vapes—Lost Mary Glayce, ELFBAR ELFA “Stein,” VOZOL SLEEK—highlighting rechargeability, pod swaps, and a compliance- and sustainability-led trend.
Oct.27 by 2FIRSTS.ai
COP11 Concludes with Major Decisions on Global Tobacco Control
COP11 Concludes with Major Decisions on Global Tobacco Control
The Eleventh Session of the Conference of the Parties (COP11) to the WHO Framework Convention on Tobacco Control (FCTC) concluded in Geneva on November 22, with 160 Parties adopting major decisions on tobacco and nicotine regulation, environmental protection, sustainable financing, and tobacco industry liability. A landmark decision mandates a complete ban on the use and sale of tobacco and all novel nicotine products across all UN premises worldwide.
Nov.24 by 2FIRSTS.ai